Bimekizumab efficacy and safety in patients with moderate-to-severe plaque psoriasis who switched from adalimumab, ustekinumab or secukinumab: results from phase III/IIIb trials
British Journal of Dermatology · 2023
DOI: 10.1093/bjd/ljac089 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift British Journal of Dermatology, 2023. Verfasst von Georgios Kokolakis und 13 weiteren Autor:innen. Beteiligte Einrichtung: Psoriasis Research and Treatment Center, Department of Dermatology, Venereology and Allergology, Charité-Universitätsmedizin Berlin, Berlin, Germany. Hauptthemen laut MEDLINE: Biological Products, Psoriasis. Die Arbeit wurde bisher 33-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: UCB Pharma, Robert Jones, UCB Pharma in accordance with Good Publication Practice.
Abstract (Originalsprache)
Background
Discontinuation of biologics is common among patients with psoriasis due to treatment failure or adverse events. To achieve improvements in disease management, patients and clinicians may choose to switch biologics.
Objectives
To evaluate the efficacy and safety of switching to bimekizumab from adalimumab, ustekinumab and secukinumab.
Methods
Data are reported for up to 80 weeks after patients switched to bimekizumab from adalimumab at week 24 in BE SURE, ustekinumab at week 52 in BE VIVID [upon entry into the BE BRIGHT open-label extension (OLE)] and secukinumab at week 48 in BE RADIANT (upon entry into the BE RADIANT OLE). Efficacy outcomes are reported by number of weeks after switching to bimekizumab and were split based on whether patients had achieved a ≥ 90% improvement from baseline in Psoriasis Area and Severity Index (PASI 90) at the time of switch. Treatment-emergent adverse events (TEAEs) are reported using exposure-adjusted incidence rates (EAIRs) per 100 patient-years.
Trial registration
BE SURE (NCT03412747), BE VIVID (NCT03370133), BE BRIGHT (NCT03598790), BE RADIANT (NCT03536884).
Results
Rapid and durable improvements in clinical responses and benefits in health-related quality of life were observed among PASI 90 nonresponders who switched to bimekizumab. Most PASI 90 nonresponders achieved PASI 90 4 weeks after switching to bimekizumab from adalimumab (67%), ustekinumab (79%) and secukinumab (53%). After 48 weeks of bimekizumab, 91%, 90% and 79% of PASI 90 nonresponders had achieved PASI 90 after switching from adalimumab, ustekinumab or secukinumab, respectively. Durable improvements were also observed for PASI 100, Investigator’s Global Assessment score 0/1, body surface area affected by psoriasis ≤ 1%, absolute PASI ≤ 2, and Dermatology Life Quality Index 0/1. Among PASI 90 responders, existing treatment responses were maintained or improved after switching to bimekizumab. The majority of TEAEs were mild or moderate. EAIRs were generally similar between active-comparator treatment periods and after switching to bimekizumab. EAIRs typically decreased with a longer duration of bimekizumab exposure.
Conclusions
High proportions of patients who did not adequately respond to adalimumab, ustekinumab or secukinumab achieved high levels of skin clearance after switching to bimekizumab. Bimekizumab was well tolerated and there were no new safety findings.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Psoriasis Research and Treatment Center, Department of Dermatology, Venereology and Allergology, Charité-Universitätsmedizin Berlin, Berlin, Germany.
- Freie Universität Berlin, Berlin, Germany.
- Humboldt-Universität zu Berlin, Berlin, Germany.
- Dermatology Centre, Salford Royal NHS Foundation Trust, Manchester NIHR Biomedical Research Centre, The University of Manchester, Manchester, UK.
- Yale University, New Haven, CT, USA.
- Central Connecticut Dermatology Research, Cromwell, CT, USA.
ORCID-Profile: Georgios Kokolakis, Richard B Warren, Bruce Strober, Melinda Gooderham
Förderung
- UCB Pharma
- Robert Jones
- UCB Pharma in accordance with Good Publication Practice
- NIHR
Zitieren
APA
Kokolakis, G., Warren, R. B., Strober, B., Blauvelt, A., Puig, L., Morita, A., Gooderham, M., Körber, A., Vanvoorden, V., Wang, M., de Cuyper, D., Madden, C., Nunez Gomez, N., & Lebwohl, M. (2023). Bimekizumab efficacy and safety in patients with moderate-to-severe plaque psoriasis who switched from adalimumab, ustekinumab or secukinumab: results from phase III/IIIb trials. British Journal of Dermatology. https://doi.org/10.1093/bjd/ljac089
Vancouver
Kokolakis G, Warren RB, Strober B, Blauvelt A, Puig L, Morita A, et al. Bimekizumab efficacy and safety in patients with moderate-to-severe plaque psoriasis who switched from adalimumab, ustekinumab or secukinumab: results from phase III/IIIb trials. British Journal of Dermatology. 2023. doi:10.1093/bjd/ljac089
BibTeX
@article{Kokolakis2023,
author = {Kokolakis, Georgios and Warren, Richard B and Strober, Bruce and Blauvelt, Andrew and Puig, Luis and Morita, Akimichi and Gooderham, Melinda and Körber, Andreas and Vanvoorden, Veerle and Wang, Maggie and de Cuyper, Dirk and Madden, Cynthia and Nunez Gomez, Natalie and Lebwohl, Mark},
title = {Bimekizumab efficacy and safety in patients with moderate-to-severe plaque psoriasis who switched from adalimumab, ustekinumab or secukinumab: results from phase III/IIIb trials},
journal = {British Journal of Dermatology},
year = {2023},
doi = {10.1093/bjd/ljac089}
}
EUVIMED